Literature DB >> 9021212

Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against beta-lactamases that belong to groups 1, 2b, and 2be.

L S Tzouvelekis1, M Gazouli, E E Prinarakis, E Tzelepi, N J Legakis.   

Abstract

The inhibitory activity of the penicillanic acid sulfone Ro 48-1220 against group 1, 2b, and 2be beta-lactamases was evaluated. Ro 48-1220 inhibited TEM and SHV as effectively as clavulanate and tazobactam. It also inhibited group 1 beta-lactamases at lower concentrations than tazobactam. Ro 48-1220, at a concentration of 4 micrograms/ml, protected ceftriaxone and ceftazidime against strains producing group 1 and 2be beta-lactamases.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9021212      PMCID： PMC163734     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Characterization of a novel SHV beta-lactamase variant that resembles the SHV-5 enzyme.

Authors:  E E Prinarakis; E Tzelepi; M Gazouli; A F Mentis; L S Tzouvelekis
Journal:  FEMS Microbiol Lett       Date:  1996-06-01       Impact factor: 2.742

2.  Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.

Authors:  L Gutmann; M D Kitzis; S Yamabe; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 3.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

4.  Nucleotide sequence of a plasmid-mediated cephalosporinase gene (blaLAT-1) found in Klebsiella pneumoniae.

Authors:  L S Tzouvelekis; E Tzelepi; A F Mentis
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases.

Authors:  P A Bradford; N V Jacobus; N Bhachech; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase.

Authors:  G L French; K P Shannon; N Simmons
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

7.  High prevalence of stably derepressed class-I beta-lactamase expression in multiresistant clinical isolates of Enterobacter cloacae from Greek hospitals.

Authors:  E Tzelepi; L S Tzouvelekis; A C Vatopoulos; A F Mentis; A Tsakris; N J Legakis
Journal:  J Med Microbiol       Date:  1992-08       Impact factor: 2.472

8.  Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.

Authors:  H G Richter; P Angehrn; C Hubschwerlen; M Kania; M G Page; J L Specklin; F K Winkler
Journal:  J Med Chem       Date:  1996-09-13       Impact factor: 7.446

9.  Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.

Authors:  K S Thomson; D A Weber; C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

10.  Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae.

Authors:  J P Quinn; D Miyashiro; D Sahm; R Flamm; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191
View more
  10 in total

Review 1.  Plasmid-determined AmpC-type beta-lactamases.

Authors:  Alain Philippon; Guillaume Arlet; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Escherichia coli with a self-transferable, multiresistant plasmid coding for metallo-beta-lactamase VIM-1.

Authors:  Vivi Miriagou; Eva Tzelepi; Dimitra Gianneli; Leonidas S Tzouvelekis
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

3.  Use of beta-lactamase inhibitors in disk tests to detect plasmid-mediated AmpC beta-lactamases.

Authors:  Jennifer A Black; Kenneth S Thomson; Johann D D Pitout
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

4.  CMY-13, a novel inducible cephalosporinase encoded by an Escherichia coli plasmid.

Authors:  V Miriagou; L S Tzouvelekis; L Villa; E Lebessi; A C Vatopoulos; A Carattoli; E Tzelepi
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

5.  Properties of mutant SHV-5 beta-lactamases constructed by substitution of isoleucine or valine for methionine at position 69.

Authors:  P Giakkoupi; V Miriagou; M Gazouli; E Tzelepi; N J Legakis; L S Tzouvelekis
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 6.  Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.

Authors:  Carine Bebrone; Patricia Lassaux; Lionel Vercheval; Jean-Sébastien Sohier; Adrien Jehaes; Eric Sauvage; Moreno Galleni
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

Review 7.  The development of beta-lactam antibiotics in response to the evolution of beta-lactamases.

Authors:  S Y Essack
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.200

8.  Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center.

Authors:  P E Coudron; E S Moland; K S Thomson
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

Review 9.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 10.  New treatment options against gram-negative organisms.

Authors:  Matteo Bassetti; Francesca Ginocchio; Malgorzata Mikulska
Journal:  Crit Care       Date:  2011-03-22       Impact factor: 9.097
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.